Norio Yasui-Furukori
Norio Yasui-Furukori
Resistant depression, biomarkers, and comorbidity in clinical practice [0.03%]
临床实践中抵抗性抑郁、生物标志物和共病状况
Alessandro Serretti
Alessandro Serretti
Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations [0.03%]
锂和GLP-1受体激动剂在双相情感障碍中的应用：一个新兴的药物警戒信号及监测建议
Ervin Cotrik,Antônio Geraldo da Silva,Jair C Soares
Ervin Cotrik
Lithium remains a cornerstone of bipolar disorder treatment, yet it has a narrow-therapeutic index and depends on renal and volume status. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypepti...
Effectiveness and safety of long-acting aripiprazole 960 mg: preliminary findings from a prospective real-world observational study [0.03%]
长期针剂阿立哌唑960毫克的效果和安全性：一项前瞻性真实世界观察性研究的初步结果
Tiziano Prodi,Miriam Olivola,Rodolfo Leuzzi et al.
Tiziano Prodi et al.
Poor treatment adherence is a major challenge in the management of severe mental disorders, as it is associated with an increased risk of relapse, rehospitalization, symptom worsening, treatment resistance, and all-cause mortality. In 2023 ...
Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports [0.03%]
利维他塞相关躁狂和精神病发作的批判性再评价：发表病例报告的系统回顾
Aldo Stoppa,Tábatha Fernández-Plaza,Anna Giménez-Palomo et al.
Aldo Stoppa et al.
Levetiracetam (LEV) is a widely used antiepileptic but associated with psychiatric side effects. While mild reactions are common, manic and psychotic episodes are less frequent, though clinically significant. This review critically assesses...
Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder [0.03%]
扩增难治性疾病的用药选择范围：从强迫症到青少年双相情感障碍使用布瑞哌唑辅助治疗的研究展望
Yiğit Özaydin,Fevzi Tuna Ocakoğlu,Eyüp Sabri Ercan
Yiğit Özaydin
Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.) [0.03%]
关于躁动症的可接受调整速度：对Hatta等人的现实时护理抗精神病药物数据的解读（评论）
Vassilis Martiadis
Vassilis Martiadis
Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance [0.03%]
临床实践中的抗精神病药物：激越、多重用药和治疗抵抗性
Alessandro Serretti
Alessandro Serretti
Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study [0.03%]
注意缺陷多动障碍与边缘型人格障碍成人患者的哌甲酯治疗：一项前瞻性纵向研究
Giulio Emilio Brancati,Martina Marcenaro,Elena Costagli et al.
Giulio Emilio Brancati et al.
Attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) frequently co-occur. However, evidence on the clinical effects of stimulant treatment in ADHD-BPD comorbidity remains limited. This prospective study ...
Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) [0.03%]
难治性抑郁症患者焦虑型抑郁与临床预后的关系：抗抑郁药部分反应者和无反应者的难治性抑郁症比较效果研究（ASCERTAIN-TRD）
Stefania Chaikali,Clotilde Guidetti,Silvia Ioannou et al.
Stefania Chaikali et al.
Objective: Anxious depression is a negative prognostic factor linked to worse outcomes in major depressive disorder (MDD). However, its role in treatment-resistant depression (TRD) remains unclear. This secondary analysis...